JP2012505896A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012505896A5 JP2012505896A5 JP2011532190A JP2011532190A JP2012505896A5 JP 2012505896 A5 JP2012505896 A5 JP 2012505896A5 JP 2011532190 A JP2011532190 A JP 2011532190A JP 2011532190 A JP2011532190 A JP 2011532190A JP 2012505896 A5 JP2012505896 A5 JP 2012505896A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- alkenyl
- compound according
- compound
- heterocyclyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 168
- 125000000217 alkyl group Chemical group 0.000 claims 130
- 125000003342 alkenyl group Chemical group 0.000 claims 85
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 58
- 125000000623 heterocyclic group Chemical group 0.000 claims 33
- 125000005842 heteroatom Chemical group 0.000 claims 19
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 18
- 229910052760 oxygen Inorganic materials 0.000 claims 16
- 201000010099 disease Diseases 0.000 claims 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 14
- 125000006526 (C1-C2) alkyl group Chemical group 0.000 claims 13
- 125000000753 cycloalkyl group Chemical group 0.000 claims 13
- 208000031226 Hyperlipidaemia Diseases 0.000 claims 12
- 208000017169 kidney disease Diseases 0.000 claims 12
- 239000008194 pharmaceutical composition Substances 0.000 claims 12
- 239000000126 substance Substances 0.000 claims 10
- 125000001424 substituent group Chemical group 0.000 claims 10
- 229910052717 sulfur Inorganic materials 0.000 claims 9
- 125000003118 aryl group Chemical group 0.000 claims 8
- 125000001072 heteroaryl group Chemical group 0.000 claims 8
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 7
- 201000001320 Atherosclerosis Diseases 0.000 claims 6
- 208000024172 Cardiovascular disease Diseases 0.000 claims 6
- 206010048768 Dermatosis Diseases 0.000 claims 6
- 208000007342 Diabetic Nephropathies Diseases 0.000 claims 6
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 6
- 208000032928 Dyslipidaemia Diseases 0.000 claims 6
- 208000002705 Glucose Intolerance Diseases 0.000 claims 6
- 208000035150 Hypercholesterolemia Diseases 0.000 claims 6
- 206010060378 Hyperinsulinaemia Diseases 0.000 claims 6
- 206010020772 Hypertension Diseases 0.000 claims 6
- 208000013016 Hypoglycemia Diseases 0.000 claims 6
- 206010022489 Insulin Resistance Diseases 0.000 claims 6
- 206010023379 Ketoacidosis Diseases 0.000 claims 6
- 208000007976 Ketosis Diseases 0.000 claims 6
- 208000017170 Lipid metabolism disease Diseases 0.000 claims 6
- 208000001145 Metabolic Syndrome Diseases 0.000 claims 6
- 206010028980 Neoplasm Diseases 0.000 claims 6
- 208000008589 Obesity Diseases 0.000 claims 6
- 206010030113 Oedema Diseases 0.000 claims 6
- 201000001880 Sexual dysfunction Diseases 0.000 claims 6
- 208000007536 Thrombosis Diseases 0.000 claims 6
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims 6
- 201000011510 cancer Diseases 0.000 claims 6
- 208000033679 diabetic kidney disease Diseases 0.000 claims 6
- 239000003814 drug Substances 0.000 claims 6
- 201000006549 dyspepsia Diseases 0.000 claims 6
- 201000001421 hyperglycemia Diseases 0.000 claims 6
- 230000003451 hyperinsulinaemic effect Effects 0.000 claims 6
- 201000008980 hyperinsulinism Diseases 0.000 claims 6
- 208000020346 hyperlipoproteinemia Diseases 0.000 claims 6
- 208000006575 hypertriglyceridemia Diseases 0.000 claims 6
- 230000002218 hypoglycaemic effect Effects 0.000 claims 6
- 235000020824 obesity Nutrition 0.000 claims 6
- 201000009104 prediabetes syndrome Diseases 0.000 claims 6
- 150000003839 salts Chemical class 0.000 claims 6
- 231100000872 sexual dysfunction Toxicity 0.000 claims 6
- 208000017520 skin disease Diseases 0.000 claims 6
- 208000011580 syndromic disease Diseases 0.000 claims 6
- -1 wherein Chemical group 0.000 claims 6
- 125000000041 C6-C10 aryl group Chemical group 0.000 claims 4
- 125000003545 alkoxy group Chemical group 0.000 claims 4
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 4
- 208000024891 symptom Diseases 0.000 claims 4
- 229940124597 therapeutic agent Drugs 0.000 claims 4
- 125000006564 (C4-C8) cycloalkyl group Chemical group 0.000 claims 3
- ZOBPZXTWZATXDG-UHFFFAOYSA-N 1,3-thiazolidine-2,4-dione Chemical compound O=C1CSC(=O)N1 ZOBPZXTWZATXDG-UHFFFAOYSA-N 0.000 claims 2
- 108010067722 Dipeptidyl Peptidase 4 Proteins 0.000 claims 2
- 102100025012 Dipeptidyl peptidase 4 Human genes 0.000 claims 2
- 229940123464 Thiazolidinedione Drugs 0.000 claims 2
- 125000002877 alkyl aryl group Chemical group 0.000 claims 2
- 125000002619 bicyclic group Chemical group 0.000 claims 2
- 125000000392 cycloalkenyl group Chemical group 0.000 claims 2
- 239000003085 diluting agent Substances 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 125000000455 heteroaryl-fused-cycloalkyl group Chemical group 0.000 claims 2
- 239000003112 inhibitor Substances 0.000 claims 2
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical group CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 claims 2
- 229960003105 metformin Drugs 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- 125000002950 monocyclic group Chemical group 0.000 claims 2
- 125000004115 pentoxy group Chemical group [*]OC([H])([H])C([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 229920006395 saturated elastomer Polymers 0.000 claims 2
- 125000003341 7 membered heterocyclic group Chemical group 0.000 claims 1
- 241000257303 Hymenoptera Species 0.000 claims 1
- 125000005137 alkenylsulfonyl group Chemical group 0.000 claims 1
- 125000004948 alkyl aryl alkyl group Chemical group 0.000 claims 1
- 125000001374 aryl-fused-cycloalkyl group Chemical group 0.000 claims 1
- 125000005843 halogen group Chemical group 0.000 claims 1
- 0 CC1C(C)(C)*CC1 Chemical compound CC1C(C)(C)*CC1 0.000 description 2
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US19627108P | 2008-10-15 | 2008-10-15 | |
| US61/196,271 | 2008-10-15 | ||
| PCT/US2009/060549 WO2010045258A2 (en) | 2008-10-15 | 2009-10-13 | Spirocyclic gpr40 modulators |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012505896A JP2012505896A (ja) | 2012-03-08 |
| JP2012505896A5 true JP2012505896A5 (enExample) | 2012-11-22 |
| JP5551707B2 JP5551707B2 (ja) | 2014-07-16 |
Family
ID=41835743
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011532190A Expired - Fee Related JP5551707B2 (ja) | 2008-10-15 | 2009-10-13 | スピロ環ｇｐｒ４０調節因子 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US8748462B2 (enExample) |
| EP (1) | EP2358656B1 (enExample) |
| JP (1) | JP5551707B2 (enExample) |
| AU (1) | AU2009303475B2 (enExample) |
| CA (1) | CA2739888C (enExample) |
| ES (1) | ES2450567T3 (enExample) |
| MX (1) | MX2011003917A (enExample) |
| WO (1) | WO2010045258A2 (enExample) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5809157B2 (ja) | 2010-10-08 | 2015-11-10 | 持田製薬株式会社 | 環状アミド誘導体 |
| EP2646425B1 (en) * | 2010-12-01 | 2015-06-10 | Boehringer Ingelheim International Gmbh | Indanyloxydihydrobenzofuranylacetic acids useful for the treatment of metabolic syndrome |
| TW201247636A (en) | 2011-04-27 | 2012-12-01 | Mochida Pharm Co Ltd | Novel 3-hydroxyisothiazole 1-oxide derivatives |
| EP2716636A4 (en) | 2011-04-28 | 2014-11-26 | Mochida Pharm Co Ltd | CYCLIC AMIDE DERIVATIVE |
| EA201490052A1 (ru) * | 2011-06-23 | 2014-04-30 | Вайамет Фармасьютикалс, Инк. | Соединения, ингибирующие металлоферменты |
| TW201341356A (zh) | 2012-02-28 | 2013-10-16 | 皮拉馬爾企業有限公司 | 作為gpr促效劑之苯基烷酸衍生物 |
| US8642585B2 (en) | 2012-03-26 | 2014-02-04 | Boehringer Ingelheim International Gmbh | Indanyloxydihydrobenzofuranylacetic acids |
| US8809376B2 (en) | 2012-04-30 | 2014-08-19 | Boehringer Ingelheim International Gmbh | Indanyloxydihydrobenzofuranylacetic acids |
| JP6214636B2 (ja) * | 2012-05-17 | 2017-10-18 | アレイ バイオファーマ、インコーポレイテッド | ヒドロキシル化シクロペンチルピリミジン化合物を作製するためのプロセス |
| HK1210825A1 (en) | 2012-07-11 | 2016-05-06 | Elcelyx Therapeutics, Inc. | Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk |
| WO2014022528A1 (en) | 2012-08-02 | 2014-02-06 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
| US20140163025A1 (en) | 2012-12-07 | 2014-06-12 | Boehringer Ingelheim International Gmbh | Indanyloxydihydrobenzofuranylacetic acids |
| WO2014130608A1 (en) | 2013-02-22 | 2014-08-28 | Merck Sharp & Dohme Corp. | Antidiabetic bicyclic compounds |
| AR096041A1 (es) | 2013-04-17 | 2015-12-02 | Piramal Entpr Ltd | Derivados de ácido carboxílico alquilo sustituidos como agonistas rpg |
| JP5975081B2 (ja) | 2013-09-30 | 2016-08-23 | ダイキン工業株式会社 | 含フッ素ビアリール化合物の製造方法 |
| WO2015051496A1 (en) | 2013-10-08 | 2015-04-16 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
| EP3068788A1 (en) | 2013-11-14 | 2016-09-21 | Cadila Healthcare Limited | Novel heterocyclic compounds |
| US10519115B2 (en) | 2013-11-15 | 2019-12-31 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
| EP3076959B1 (en) | 2013-12-04 | 2018-07-04 | Merck Sharp & Dohme Corp. | Antidiabetic bicyclic compounds |
| WO2015089809A1 (en) | 2013-12-19 | 2015-06-25 | Merck Sharp & Dohme Corp. | Antidiabetic substituted heteroaryl compounds |
| US10059667B2 (en) | 2014-02-06 | 2018-08-28 | Merck Sharp & Dohme Corp. | Antidiabetic compounds |
| CN105001212B (zh) * | 2014-04-16 | 2018-01-16 | 江苏柯菲平医药股份有限公司 | 稠环化合物及其制备方法和应用 |
| WO2015176267A1 (en) | 2014-05-22 | 2015-11-26 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
| WO2016019587A1 (en) | 2014-08-08 | 2016-02-11 | Merck Sharp & Dohme Corp. | [7, 6]-fused bicyclic antidiabetic compounds |
| EP3177282B1 (en) | 2014-08-08 | 2021-10-06 | Merck Sharp & Dohme Corp. | Antidiabetic bicyclic compounds |
| WO2016022446A1 (en) | 2014-08-08 | 2016-02-11 | Merck Sharp & Dohme Corp. | [5,6]-fused bicyclic antidiabetic compounds |
| EP3177287B1 (en) | 2014-08-08 | 2022-02-23 | Merck Sharp & Dohme Corp. | Antidiabetic bicyclic compounds |
| WO2017172505A1 (en) | 2016-03-29 | 2017-10-05 | Merck Sharp & Dohme Corp. | Antidiabetic bicyclic compounds |
| US11072602B2 (en) | 2016-12-06 | 2021-07-27 | Merck Sharp & Dohme Corp. | Antidiabetic heterocyclic compounds |
| EP3558298B1 (en) | 2016-12-20 | 2026-03-11 | Merck Sharp & Dohme LLC | Antidiabetic spirochroman compounds |
| JP7050791B2 (ja) | 2017-01-26 | 2022-04-08 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | ベンジルオキシピリジルシクロプロパンカルボン酸、その医薬組成物及び使用 |
| JP7023969B2 (ja) | 2017-01-26 | 2022-02-22 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | ベンジルアミノピリジルシクロプロパンカルボン酸、その医薬組成物及び使用 |
| CN110248929B (zh) | 2017-01-26 | 2023-05-12 | 勃林格殷格翰国际有限公司 | 苄基氨基吡嗪基环丙烷甲酸、其药物组合物和用途 |
| CN110312714B (zh) * | 2017-01-26 | 2022-12-09 | 勃林格殷格翰国际有限公司 | 苄基氧基吡嗪基环丙烷甲酸、其药物组合物和用途 |
| EP3580222B1 (en) | 2017-02-08 | 2021-04-07 | Boehringer Ingelheim International GmbH | Indanylaminoazadihydrobenzofuranylacetic acids, pharmaceutical compositions for the treatment of diabetes |
| AR111199A1 (es) | 2017-03-31 | 2019-06-12 | Takeda Pharmaceuticals Co | Compuesto aromático agonista de gpr40 |
| BR102018007822A2 (pt) | 2017-04-20 | 2018-11-06 | Gilead Sciences, Inc. | composto, métodos para inibir pd-1, pd-l1 e/ou interação de pd-1/pd-l1 e para tratamento de câncer, composição farmacêutica, e, kit para tratamento de ou prevenção de câncer ou uma doença ou condição |
| US11225471B2 (en) | 2017-11-16 | 2022-01-18 | Merck Sharp & Dohme Corp. | Antidiabetic bicyclic compounds |
| KR102708681B1 (ko) | 2018-02-13 | 2024-09-26 | 길리애드 사이언시즈, 인코포레이티드 | Pd-1/pd-l1 억제제 |
| WO2019170543A1 (en) | 2018-03-07 | 2019-09-12 | Bayer Aktiengesellschaft | Identification and use of erk5 inhibitors |
| EP4600247A3 (en) | 2018-04-19 | 2025-11-19 | Gilead Sciences, Inc. | Pd-1/pd-l1 inhibitors |
| UA126421C2 (uk) | 2018-07-13 | 2022-09-28 | Гіліад Сайєнсіз, Інк. | Інгібітори pd-1/pd-l1 |
| US11236085B2 (en) | 2018-10-24 | 2022-02-01 | Gilead Sciences, Inc. | PD-1/PD-L1 inhibitors |
| CN112010881B (zh) * | 2019-05-30 | 2021-09-03 | 中国科学院兰州化学物理研究所 | 一种烯基硼化合物及其制备方法与应用 |
| CN119462631A (zh) * | 2024-10-09 | 2025-02-18 | 广东莱佛士制药技术有限公司 | 一种司巴生坦中间体的合成方法 |
Family Cites Families (73)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE305216B (enExample) * | 1965-09-17 | 1968-10-21 | Astra Apotekarnes Kem Fab | |
| FR2359135A1 (fr) | 1976-07-22 | 1978-02-17 | Hexachimie | Nouvelles phenoxyhydroxypropylamines, procede pour les preparer et leur application en therapeutique |
| US4760089A (en) * | 1985-09-09 | 1988-07-26 | Smithkline Beckman Corporation | Irreversible dopamine-β-hydroxylase inhibitors |
| PT85081A (en) | 1986-06-19 | 1987-07-01 | Smithkline Beckman Corp | Irreversible dopamine-beta-hydroxylase inhibitors |
| GB8917069D0 (en) | 1989-07-26 | 1989-09-13 | Merck Sharp & Dohme | Therapeutic agents |
| DE4019307A1 (de) * | 1990-06-16 | 1991-12-19 | Bayer Ag | 2-methoximinocarbonsaeureester |
| CA2135173A1 (en) | 1992-05-20 | 1993-11-25 | Bruce E. Witzel | Ester derivatives of 4-aza-steroids |
| AU668180B2 (en) | 1992-05-20 | 1996-04-26 | Merck & Co., Inc. | 17-ethers and thioethers of 4-aza-steroids |
| DE4241632A1 (de) | 1992-12-10 | 1994-06-16 | Thomae Gmbh Dr K | Carbonsäurederivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung |
| JP3894949B2 (ja) | 1993-06-30 | 2007-03-22 | ザ、ウェルカム、ファンデーション、リミテッド | 抗アテローム性動脈硬化症ジアリール化合物 |
| US5463063A (en) | 1993-07-02 | 1995-10-31 | Celgene Corporation | Ring closure of N-phthaloylglutamines |
| US6037367A (en) * | 1995-07-14 | 2000-03-14 | Smithkline Beecham Corporation | Substituted-pent-4-ynoic acids |
| US5795900A (en) | 1995-10-03 | 1998-08-18 | Abbott Laboratories | Symmetrical bis-heteroaryl-methoxy-phenylalkyl carboxylates as inhibitors of leukotriene biosynthesis |
| JPH10316641A (ja) | 1997-03-14 | 1998-12-02 | Sankyo Co Ltd | カルボン酸誘導体 |
| WO1999011255A1 (en) | 1997-08-28 | 1999-03-11 | Ono Pharmaceutical Co., Ltd. | Peroxisome proliferator-activated receptor controllers |
| US6645939B1 (en) * | 1997-11-24 | 2003-11-11 | Merck & Co., Inc. | Substituted β-alanine derivatives as cell adhesion inhibitors |
| JP4345230B2 (ja) * | 1998-03-10 | 2009-10-14 | 小野薬品工業株式会社 | カルボン酸誘導体およびその誘導体を有効成分として含有する薬剤 |
| DE19941567A1 (de) | 1998-09-05 | 2000-04-20 | Merck Patent Gmbh | Neue flüssigkristalline Verbindungen |
| WO2000063196A1 (en) | 1999-04-20 | 2000-10-26 | Novo Nordisk A/S | New compounds, their preparation and use |
| EP1177186B1 (en) * | 1999-05-05 | 2004-03-31 | Aventis Pharma Limited | Ureas and their use as cell adhesion modulators |
| GB9914977D0 (en) | 1999-06-25 | 1999-08-25 | Glaxo Group Ltd | Chemical compounds |
| GB9927056D0 (en) | 1999-11-17 | 2000-01-12 | Karobio Ab | Thyroid receptor antagonists for the treatment of cardiac and metabolic disorders |
| AU1624801A (en) | 1999-11-19 | 2001-05-30 | Corvas International, Inc. | Plasminogen activator inhibitor antagonists related applications |
| JP2001242165A (ja) | 2000-02-25 | 2001-09-07 | Dai Ichi Seiyaku Co Ltd | 採血用試薬 |
| JP2002003368A (ja) | 2000-06-23 | 2002-01-09 | Saitama Daiichi Seiyaku Kk | 経皮吸収又は経粘膜吸収用の製剤 |
| GB0031107D0 (en) | 2000-12-20 | 2001-01-31 | Glaxo Group Ltd | Chemical compounds |
| GB0031527D0 (en) | 2000-12-22 | 2001-02-07 | Smithkline Beecham Plc | New use |
| US6906046B2 (en) | 2000-12-22 | 2005-06-14 | Celltech R & D Inc. | Pharmaceutical uses and synthesis of benzobicyclooctanes |
| DE60139025D1 (de) * | 2000-12-28 | 2009-07-30 | Takeda Pharmaceutical | Alkansäurederivate, verfahren zu deren herstellung und deren verwendung |
| TWI311133B (en) | 2001-04-20 | 2009-06-21 | Eisai R&D Man Co Ltd | Carboxylic acid derivativeand the salt thereof |
| EA200400011A1 (ru) | 2001-06-07 | 2004-06-24 | Эли Лилли Энд Компани | Модуляторы рецепторов, активируемых пролифераторами пероксисом (prar) |
| CA2475434C (en) * | 2002-02-07 | 2011-04-05 | Hitoshi Endou | Aromatic amino acid derivatives and medicinal compositions |
| US7214495B2 (en) * | 2002-02-14 | 2007-05-08 | Takeda Pharmaceutical Company Limited | Screening method |
| US20030207924A1 (en) | 2002-03-07 | 2003-11-06 | Xue-Min Cheng | Compounds that modulate PPAR activity and methods of preparation |
| US6875780B2 (en) * | 2002-04-05 | 2005-04-05 | Warner-Lambert Company | Compounds that modulate PPAR activity and methods for their preparation |
| US20060148858A1 (en) | 2002-05-24 | 2006-07-06 | Tsuyoshi Maekawa | 1, 2-Azole derivatives with hypoglycemic and hypolipidemic activity |
| GB0214149D0 (en) | 2002-06-19 | 2002-07-31 | Glaxo Group Ltd | Chemical compounds |
| US7553867B2 (en) | 2002-09-06 | 2009-06-30 | Takeda Pharmaceutical Company Limited | Furan or thiophene derivative and medicinal use thereof |
| EP1559422B1 (en) | 2002-11-08 | 2014-04-30 | Takeda Pharmaceutical Company Limited | Receptor function controlling agent |
| US6906406B2 (en) * | 2002-12-19 | 2005-06-14 | Freescale Semiconductor, Inc. | Multiple dice package |
| WO2004092117A1 (en) | 2003-04-07 | 2004-10-28 | Kalypsys, Inc. | Para-sulfonyl substituted phenyl compounds as modulators of ppars |
| EP1630152A4 (en) * | 2003-05-30 | 2009-09-23 | Takeda Pharmaceutical | CONDENSED CYCLIC COMPOUND |
| JP4805552B2 (ja) * | 2003-05-30 | 2011-11-02 | 武田薬品工業株式会社 | 縮合環化合物 |
| WO2005051890A1 (en) | 2003-11-19 | 2005-06-09 | Smithkline Beecham Corporation | Aminophenylcyclopropyl carboxylic acids and derivatives as agonists to gpr40 |
| AU2004299456B2 (en) | 2003-12-17 | 2010-10-07 | Merck Sharp & Dohme Corp. | (3,4-disubstituted)propanoic carboxylates as S1P (Edg) receptor agonists |
| CA2551610A1 (en) * | 2003-12-25 | 2005-07-14 | Takeda Pharmaceutical Company Limited | 3-(4-benzyloxyphenyl)propanoic acid derivatives |
| JP4855777B2 (ja) | 2003-12-26 | 2012-01-18 | 武田薬品工業株式会社 | フェニルプロパン酸誘導体 |
| EP1723132A1 (en) * | 2004-02-12 | 2006-11-22 | Asterand Uk Limited | Ep2 receptor agonists |
| EA011010B1 (ru) * | 2004-02-27 | 2008-12-30 | Эмджен, Инк. | Соединения, модулирующие рецептор gpr40, фармацевтическая композиция, способ лечения заболеваний, чувствительных к модулированию рецептора gpr40 (варианты), способ модулирования функции gpr40 (варианты) и способ модулирования циркулирующей концентрации инсулина |
| WO2005087710A1 (ja) | 2004-03-15 | 2005-09-22 | Takeda Pharmaceutical Company Limited | アミノフェニルプロパン酸誘導体 |
| EP2253315A1 (en) | 2004-03-30 | 2010-11-24 | Takeda Pharmaceutical Company Limited | Alkoxyphenylpropanoic acid derivatives |
| JP2007269630A (ja) | 2004-06-23 | 2007-10-18 | Toudai Tlo Ltd | インスリン分泌促進剤 |
| US20060003344A1 (en) * | 2004-06-30 | 2006-01-05 | Pfizer Inc. | Methods related to a single nucleotide polymorphism of the G protein coupled receptor, GPR40 |
| JP2007284350A (ja) | 2004-07-27 | 2007-11-01 | Takeda Chem Ind Ltd | 糖尿病治療剤 |
| JP2008528590A (ja) | 2005-01-28 | 2008-07-31 | メルク エンド カムパニー インコーポレーテッド | 抗糖尿病性二環式化合物 |
| US7759493B2 (en) | 2005-01-31 | 2010-07-20 | Merck Sharp & Dohme Corp. | Antidiabetic bicyclic compounds |
| US7465804B2 (en) * | 2005-05-20 | 2008-12-16 | Amgen Inc. | Compounds, pharmaceutical compositions and methods for their use in treating metabolic disorders |
| WO2007008541A2 (en) | 2005-07-08 | 2007-01-18 | Kalypsys, Inc. | Cellular cholesterol absorption modifiers |
| EP1916234B1 (en) | 2005-07-29 | 2014-11-12 | Takeda Pharmaceutical Company Limited | Cyclopropanecarboxylic acid compound |
| EP1924546A1 (en) * | 2005-09-14 | 2008-05-28 | Amgen, Inc | Conformationally constrained 3- (4-hydroxy-phenyl) - substituted-propanoic acids useful for treating metabolic disorders |
| WO2007049050A2 (en) | 2005-10-27 | 2007-05-03 | Heptahelix Ab | Modulators of gpr40 for the treatment of diabetes |
| CA2646430A1 (en) * | 2006-03-14 | 2007-09-20 | Amgen Inc. | Bicyclic carboxylic acid derivatives useful for treating metabolic disorders |
| TW200815377A (en) | 2006-04-24 | 2008-04-01 | Astellas Pharma Inc | Oxadiazolidinedione compound |
| DE102006021874B4 (de) | 2006-05-11 | 2008-03-27 | Sanofi-Aventis | 4,5-Diphenyl-pyrimidinyl-amino substituierte Carbonsäuren, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| DE102006021878A1 (de) | 2006-05-11 | 2007-11-15 | Sanofi-Aventis | Phenylamino-benzoxazol substituierte Carbonsäuren, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| DE102006021872B4 (de) | 2006-05-11 | 2008-04-17 | Sanofi-Aventis | 4,5-Diphenyl-pyrimidinyl-oxy oder -mercapto substituierte Carbonsäuren, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| ATE552245T1 (de) * | 2006-05-15 | 2012-04-15 | Merck Sharp & Dohme | Antidiabetische bicyclische verbindungen |
| CL2007001873A1 (es) | 2006-06-27 | 2008-01-04 | Takeda Pharmaceutical | Acido((3s))-6-((¨2,6-dimetil-4-(3-(metilsulfonil)-propoxi)bifenil-3-il)metoxi-2,3-dihidro-1-benzofuran-3-il)acetico o una sal del mismo |
| AU2007293028B2 (en) * | 2006-09-07 | 2012-05-31 | Amgen Inc. | Heterocyclic GPR40 modulators |
| US7687526B2 (en) * | 2006-09-07 | 2010-03-30 | Amgen Inc. | Benzo-fused compounds for use in treating metabolic disorders |
| WO2008054675A2 (en) | 2006-10-31 | 2008-05-08 | Merck & Co., Inc. | Antidiabetic bicyclic compounds |
| CA2683751C (en) | 2007-04-16 | 2013-01-08 | Amgen Inc. | Substituted biphenyl phenoxy-, thiophenyl- and aminophenylpropanoic acid gpr40 modulators |
| KR20100090249A (ko) * | 2007-10-10 | 2010-08-13 | 암젠 인크 | 치환된 비페닐 ｇｒｐ４０ 조절제 |
-
2009
- 2009-10-13 US US13/119,951 patent/US8748462B2/en active Active
- 2009-10-13 EP EP09741123.5A patent/EP2358656B1/en active Active
- 2009-10-13 JP JP2011532190A patent/JP5551707B2/ja not_active Expired - Fee Related
- 2009-10-13 ES ES09741123.5T patent/ES2450567T3/es active Active
- 2009-10-13 MX MX2011003917A patent/MX2011003917A/es active IP Right Grant
- 2009-10-13 CA CA2739888A patent/CA2739888C/en not_active Expired - Fee Related
- 2009-10-13 WO PCT/US2009/060549 patent/WO2010045258A2/en not_active Ceased
- 2009-10-13 AU AU2009303475A patent/AU2009303475B2/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011500562A5 (enExample) | ||
| CN1069901C (zh) | N－苄基二氧代噻唑烷基苯甲酰胺衍生物及其制造方法 | |
| Darwish et al. | Design, synthesis, and biological evaluation of novel thiazolidinediones as PPARγ/FFAR1 dual agonists | |
| JP7352297B2 (ja) | ピリドン誘導体と、その組成物、並びにそれらが抗ウイルス薬物としての応用 | |
| CA2739888C (en) | Spirocyclic gpr40 modulators | |
| CA2662305A1 (en) | Heterocyclic gpr40 modulators | |
| CN1205695A (zh) | N－取代二氧代噻唑烷基苯甲酰胺衍生物及其制备方法 | |
| JP2009530281A5 (enExample) | ||
| JP2019069940A (ja) | スルファモイル−アリールアミド及びｂ型肝炎の治療のための薬剤としてのその使用 | |
| WO2007126043A1 (ja) | チアゾール環を含むカルボン酸誘導体の医薬用途 | |
| Zhu et al. | N 2-Selective iodofunctionalization of olefins with NH-1, 2, 3-triazoles to provide N 2-alkyl-substituted 1, 2, 3-triazoles | |
| CN102239164A (zh) | 2h-色烯化合物及其衍生物 | |
| TW201427959A (zh) | 新穎化合物 | |
| JP2018528159A (ja) | 芳香族スルホンアミド誘導体 | |
| JP2017537111A (ja) | ヘテロ環式誘導体およびその使用 | |
| CN1150185C (zh) | 被杂环化合物取代的丙醇胺衍生物、其制备方法、含有所述化合物的药物组合物及其用途 | |
| CN109996797A (zh) | 作为乳酸脱氢酶的抑制剂的1h-吡唑-1-基-噻唑及其使用方法 | |
| JP2005532392A5 (enExample) | ||
| JPH0912575A (ja) | ベンゾオキサジンおよびベンゾチアジン誘導体 | |
| WO2024102625A1 (en) | Glucagon-like peptide 1 receptor agonists | |
| CN120344520A (zh) | 胰高血糖素样肽1受体激动剂 | |
| Kallemeyn et al. | Development of a Large-Scale Route to Glecaprevir: Synthesis of the Macrocycle via Intramolecular Etherification | |
| ZA200408057B (en) | Heterocyclic amide derivatives for the treatment of diabetes and other diseases | |
| WO2011116663A1 (zh) | 2',2-双噻唑非核苷类化合物及其制备方法、药物组合物和作为肝炎病毒抑制剂的用途 | |
| CA2537079A1 (en) | Fluorene derivative |